-
公开(公告)号：US08333995B2
公开(公告)日：2012-12-18
申请号：US11127704
申请日：2005-05-12
Applicant: Larry Brown , Vered Bisker-Leib , Debra LaFreniere , John McGeehan , Julia Rashba-Step , Terrence Scott
Inventor： Larry Brown , Vered Bisker-Leib , Debra LaFreniere , John McGeehan , Julia Rashba-Step , Terrence Scott
IPC: A61K39/395
CPC classification number: C07K16/2896 , A61K9/0019 , A61K9/10 , A61K9/1688 , C07K16/2866 , C07K16/36 , C07K2317/24
Abstract: The present invention relates to compositions of methods of making and compositions small compositions of particles of an active agent. In accordance with the method of production, the active agent is dissolved in an aqueous or aqueous-miscible solvent containing a dissolved phase-separation enhancing agent (PSEA) to form a solution in a single liquid phase. The solution is subjected to a liquid-solid phase separation to cause the active agent to form small spherical that are substantially amorphous or non-crystalline and are injectable through fine gauge needles at high concentrations. The invention has special application for higher molecular weight proteins.
Abstract translation: 本发明涉及制备方法的组合物和组合物活性剂颗粒的小组合物。 根据生产方法，将活性剂溶解在含有溶解的相分离增强剂（PSEA）的水溶性或水溶性溶剂中以形成单一液相中的溶液。 使溶液进行液固相分离，使活性剂形成基本上无定形或非结晶的小球形，并且可以通过高浓度的细针针进行注射。 本发明对高分子量蛋白质具有特殊应用。
-
公开(公告)号：US20060024379A1
公开(公告)日：2006-02-02
申请号：US11127704
申请日：2005-05-12
Applicant: Larry Brown , Vered Bisker-Leib , Debra LaFreniere , John McGeehan , Julia Rashba-Step , Terrence Scott
Inventor： Larry Brown , Vered Bisker-Leib , Debra LaFreniere , John McGeehan , Julia Rashba-Step , Terrence Scott
IPC: A61K39/395 , A61K9/50 , A61K9/16
CPC classification number: C07K16/2896 , A61K9/0019 , A61K9/10 , A61K9/1688 , C07K16/2866 , C07K16/36 , C07K2317/24
Abstract: The present invention relates to compositions of methods of making and compositions small compositions of particles of an active agent. In accordance with the method of production, the active agent is dissolved in an aqueous or aqueous-miscible solvent containing a dissolved phase-separation enhancing agent (PSEA) to form a solution in a single liquid phase. The solution is subjected to a liquid-solid phase separation to cause the active agent to form small spherical that are substantially amorphous or non-crystalline and are injectable through fine gauge needles at high concentrations. The invention has special application for higher molecular weight proteins.
Abstract translation: 本发明涉及制备方法的组合物和组合物活性剂颗粒的小组合物。 根据生产方法，将活性剂溶解在含有溶解的相分离增强剂（PSEA）的水溶性或水溶性溶剂中以形成单一液相中的溶液。 使溶液进行液固相分离，使活性剂形成基本上无定形或非结晶的小球形，并且可以通过高浓度的细针针进行注射。 本发明对高分子量蛋白质具有特殊应用。
-
3.发明申请DELIVERY OF AS-OLIGONUCLEOTIDE MICROSPHERES TO INDUCE DENDRITIC CELL TOLERANCE FOR THE TREATMENT OF AUTOIMMUNE TYPE 1 DIABETES 有权递送AS-OLIGONUCLEOTIDE MICROSPHERES以诱导用于治疗自身免疫型1型糖尿病的DENDRITIC CELL ROLERANCE公开(公告)号：US20100260855A1
公开(公告)日：2010-10-14
申请号：US12822774
申请日：2010-06-24
Applicant: Larry R. Brown , Vered Bisker-Leib , Terrence L. Scott , Debra Lafreniere , Jennifer Machen , Nick Giannoukakis
Inventor： Larry R. Brown , Vered Bisker-Leib , Terrence L. Scott , Debra Lafreniere , Jennifer Machen , Nick Giannoukakis
IPC: A61K31/711 , A61K9/14 , A61K31/7088 , A61P3/10 , A61P37/06
CPC classification number: C12N15/1138 , A61K9/0019 , A61K9/1635 , A61K9/1641 , A61K9/1658 , A61K9/19 , C12N15/111 , C12N2310/11 , C12N2310/315 , C12N2320/32
Abstract: AS-oligonucleotides are delivered in microsphere form in order to induce dendritic cell tolerance, particularly in the non-obese-diabetic (NOD) mouse model. The microspheres incorporate antisense (AS) oligonucleotides. A process includes using an antisense approach to prevent an autoimmune diabetes condition in NOD mice in vivo and in situ. The oligonucleotides are targeted to bind to primary transcripts CD40, CD80, CD86 and their combinations.
Abstract translation: AS寡核苷酸以微球形式递送，以诱导树突细胞耐受，特别是在非肥胖 - 糖尿病（NOD）小鼠模型中。 微球合并反义（AS）寡核苷酸。 一种方法包括使用反义方法在体内和原位抑制NOD小鼠中的自身免疫性糖尿病状况。 靶向寡核苷酸以结合初级转录物CD40，CD80，CD86及其组合。
-
4.发明申请Delivery of as-oligonucleotide microspheres to induce dendritic cell tolerance for the treatment of autoimmune type 1 diabetes 有权递送寡核苷酸微球以诱导树突状细胞耐受治疗自身免疫性1型糖尿病公开(公告)号：US20060024240A1
公开(公告)日：2006-02-02
申请号：US11127360
申请日：2005-05-12
Applicant: Larry Brown , Vered Bisker-Leib , Terrence Scott , Debra Lafreniere , Jennifer Mochen , Nick Giannoukakls
Inventor： Larry Brown , Vered Bisker-Leib , Terrence Scott , Debra Lafreniere , Jennifer Mochen , Nick Giannoukakls
CPC classification number: C12N15/1138 , A61K9/0019 , A61K9/1635 , A61K9/1641 , A61K9/1658 , A61K9/19 , C12N15/111 , C12N2310/11 , C12N2310/315 , C12N2320/32
Abstract: AS-oligonucleotides are delivered in microsphere form in order to induce dendritic cell tolerance, particularly in the non-obese-diabetic (NOD) mouse model. The microspheres incorporate antisense (AS) oligonucleotides. A process includes using an antisense approach to prevent an autoimmune diabetes condition in NOD mice in vivo and in situ. The oligonucleotides are targeted to bind to primary transcripts CD40, CD80, CD86 and their combinations.
Abstract translation: AS寡核苷酸以微球形式递送，以诱导树突细胞耐受，特别是在非肥胖 - 糖尿病（NOD）小鼠模型中。 微球合并反义（AS）寡核苷酸。 一种方法包括使用反义方法在体内和原位抑制NOD小鼠中的自身免疫性糖尿病状况。 靶向寡核苷酸以结合初级转录物CD40，CD80，CD86及其组合。
-
公开(公告)号：US09339465B2
公开(公告)日：2016-05-17
申请号：US12878783
申请日：2010-09-09
Applicant: Terrence Scott , Debra Lafreniere , Vered Bisker-Leib , Larry Brown
Inventor： Terrence Scott , Debra Lafreniere , Vered Bisker-Leib , Larry Brown
IPC: A61K9/14 , A61K31/7088 , A61P37/00 , B32B5/16 , A61K9/16 , C12N15/11 , C12N15/113
CPC classification number: A61K9/1629 , C12N15/111 , C12N15/113 , C12N15/1138 , C12N2310/11 , C12N2310/14 , C12N2310/315 , C12N2320/32 , Y10T428/2982
Abstract: Nucleic acids are prepared by dissolving compounds containing them in a suitable solvent or solvent system and forming microspheres from the resulting solution. The microspheres are administered to an individual as protection from conditions where delivery of nucleic acids is useful, such as in treatment of autoimmune disease.
Abstract translation: 通过将含有它们的化合物溶解在合适的溶剂或溶剂体系中并从所得溶液中形成微球体来制备核酸。 将微球施用于个体，作为防止核酸递送有用的条件的保护，例如治疗自身免疫性疾病。
-
Patent Agency Ranking
6.发明授权Delivery of AS-oligonucleotide microspheres to induce dendritic cell tolerance for the treatment of autoimmune type 1 diabetes 有权递送AS-寡核苷酸微球以诱导树突细胞耐受治疗自身免疫性1型糖尿病公开(公告)号：US07884085B2
公开(公告)日：2011-02-08
申请号：US11127360
申请日：2005-05-12
Applicant: Larry R. Brown , Vered Bisker-Leib , Terrence L. Scott , Debra Lafreniere , Jennifer Machen , Nick Giannoukakls
Inventor： Larry R. Brown , Vered Bisker-Leib , Terrence L. Scott , Debra Lafreniere , Jennifer Machen , Nick Giannoukakls
CPC classification number: C12N15/1138 , A61K9/0019 , A61K9/1635 , A61K9/1641 , A61K9/1658 , A61K9/19 , C12N15/111 , C12N2310/11 , C12N2310/315 , C12N2320/32
Abstract: AS-oligonucleotides are delivered in microsphere form in order to induce dendritic cell tolerance, particularly in the non-obese-diabetic (NOD) mouse model. The microspheres incorporate antisense (AS) oligonucleotides. A process includes using an antisense approach to prevent an autoimmune diabetes condition in NOD mice in vivo and in situ. The oligonucleotides are targeted to bind to primary transcripts CD40, CD80, CD86 and their combinations.
Abstract translation: AS寡核苷酸以微球形式递送，以诱导树突细胞耐受，特别是在非肥胖 - 糖尿病（NOD）小鼠模型中。 微球合并反义（AS）寡核苷酸。 一种方法包括使用反义方法在体内和原位抑制NOD小鼠中的自身免疫性糖尿病状况。 靶向寡核苷酸以结合初级转录物CD40，CD80，CD86及其组合。
-
公开(公告)号：US20060018971A1
公开(公告)日：2006-01-26
申请号：US11127362
申请日：2005-05-12
Applicant: Terrence Scott , Debra Lafreniere , Vered Bisker-Leib , Larry Brown
Inventor： Terrence Scott , Debra Lafreniere , Vered Bisker-Leib , Larry Brown
CPC classification number: A61K9/1629 , C12N15/111 , C12N15/113 , C12N15/1138 , C12N2310/11 , C12N2310/14 , C12N2310/315 , C12N2320/32 , Y10T428/2982
Abstract: Nucleic acids are prepared by dissolving compounds containg them in a suitable solvent or solvent system and forming microshperes from the resulting solution. The microspheres are administered to an individual as protection from conditions where delivery of nuceic acids is useful, such as in treatment of autoimmune disease.
Abstract translation: 通过将含有它们的化合物溶解在合适的溶剂或溶剂体系中并从所得溶液中形成微胶粒来制备核酸。 将微球体施用于个体，作为防止尿酸递送有用的条件，例如治疗自身免疫性疾病。
-
8.发明授权Delivery of AS-oligonucleotide microspheres to induce dendritic cell tolerance for the treatment of autoimmune type 1 diabetes 有权递送AS-寡核苷酸微球以诱导树突细胞耐受治疗自身免疫性1型糖尿病公开(公告)号：US09115357B2
公开(公告)日：2015-08-25
申请号：US12822774
申请日：2010-06-24
Applicant: Larry R. Brown , Vered Bisker-Leib , Terrence L. Scott , Debra Lafreniere , Jennifer Machen , Nick Giannoukakis
Inventor： Larry R. Brown , Vered Bisker-Leib , Terrence L. Scott , Debra Lafreniere , Jennifer Machen , Nick Giannoukakis
IPC: A61K31/711 , A61K9/14 , A61K31/7088 , A61P3/10 , A61P37/06 , C12N15/113 , A61K9/00 , A61K9/16 , A61K9/19 , C12N15/11
CPC classification number: C12N15/1138 , A61K9/0019 , A61K9/1635 , A61K9/1641 , A61K9/1658 , A61K9/19 , C12N15/111 , C12N2310/11 , C12N2310/315 , C12N2320/32
Abstract: AS-oligonucleotides are delivered in microsphere form in order to induce dendritic cell tolerance, particularly in the non-obese-diabetic (NOD) mouse model. The microspheres incorporate antisense (AS) oligonucleotides. A process includes using an antisense approach to prevent an autoimmune diabetes condition in NOD mice in vivo and in situ. The oligonucleotides are targeted to bind to primary transcripts CD40, CD80, CD86 and their combinations.
Abstract translation: AS寡核苷酸以微球形式递送，以诱导树突细胞耐受，特别是在非肥胖 - 糖尿病（NOD）小鼠模型中。 微球合并反义（AS）寡核苷酸。 一种方法包括使用反义方法在体内和原位抑制NOD小鼠中的自身免疫性糖尿病状况。 靶向寡核苷酸以结合初级转录物CD40，CD80，CD86及其组合。
-
公开(公告)号：US20110033551A1
公开(公告)日：2011-02-10
申请号：US12878783
申请日：2010-09-09
Applicant: TERRENCE SCOTT , DEBRA LAFRENIERE , VERED BISKER-LEIB , LARRY BROWN
Inventor： TERRENCE SCOTT , DEBRA LAFRENIERE , VERED BISKER-LEIB , LARRY BROWN
IPC: A61K9/14 , A61K31/7088 , A61P37/00 , B32B5/16
CPC classification number: A61K9/1629 , C12N15/111 , C12N15/113 , C12N15/1138 , C12N2310/11 , C12N2310/14 , C12N2310/315 , C12N2320/32 , Y10T428/2982
Abstract: Nucleic acids are prepared by dissolving compounds containing them in a suitable solvent or solvent system and forming microspheres from the resulting solution. The microspheres are administered to an individual as protection from conditions where delivery of nucleic acids is useful, such as in treatment of autoimmune disease.
Abstract translation: 通过将含有它们的化合物溶解在合适的溶剂或溶剂体系中并从所得溶液中形成微球体来制备核酸。 将微球施用于个体，作为防止核酸递送有用的条件的保护，例如治疗自身免疫性疾病。
-
公开(公告)号：US07815941B2
公开(公告)日：2010-10-19
申请号：US11127362
申请日：2005-05-12
Applicant: Larry R. Brown , Terrence L. Scott , Debra Lafreniere , Vered Bisker-Leib
Inventor： Larry R. Brown , Terrence L. Scott , Debra Lafreniere , Vered Bisker-Leib
CPC classification number: A61K9/1629 , C12N15/111 , C12N15/113 , C12N15/1138 , C12N2310/11 , C12N2310/14 , C12N2310/315 , C12N2320/32 , Y10T428/2982
Abstract: Nucleic acids are prepared by dissolving compounds containg them in a suitable solvent or solvent system and forming microspheres from the resulting solution. The microspheres are administered to an individual as protection from conditions where delivery of nucleic acids is useful, such as in treatment of autoimmune disease.
Abstract translation: 通过将包含它们的化合物溶解在合适的溶剂或溶剂体系中并从所得溶液中形成微球体来制备核酸。 将微球施用于个体，作为防止核酸递送有用的条件的保护，例如治疗自身免疫性疾病。
-
-
-
-
-
-
-
-
-
Search Results
10
records
(took 0.01 seconds)
